Separate mechanisms for development and performance of compulsive checking in the quinpirole sensitization rat model of obsessive-compulsive disorder (OCD)

Psychopharmacology

Volumn 231, Issue 18, 2014, Pages 3707-3718

  Tucci, Mark C ^a   Dvorkin Gheva, Anna ^a   Sharma, Renee ^a   Taji, Leena ^a   Cheon, Paul ^a   Peel, John ^a   Kirk, Ashley ^a   Szechtman, Henry ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Compulsive checking behavior; Dopamine serotonin interaction; mCPP; Quinpirole; Security motivation

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; QUINPIROLE; 1-(3-CHLOROPHENYL)PIPERAZINE; DOPAMINE 3 RECEPTOR; PIPERAZINE DERIVATIVE; SEROTONIN AGONIST;

ADULT; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMPULSION; COMPULSIVE CHECKING BEHAVIOR; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; DRUG SENSITIZATION; LONG TERM CARE; LOW DRUG DOSE; MALE; MOTOR ACTIVITY; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; PRIORITY JOURNAL; RAT; RAT MODEL; AGONISTS; ANIMAL; CHEMICALLY INDUCED; COMPULSIVE BEHAVIOR; DISEASE MODEL; LONG EVANS RAT; OBSESSIVE-COMPULSIVE DISORDER;

ANIMALS; COMPULSIVE BEHAVIOR; DISEASE MODELS, ANIMAL; MALE; OBSESSIVE-COMPULSIVE DISORDER; PIPERAZINES; QUINPIROLE; RATS; RATS, LONG-EVANS; RECEPTORS, DOPAMINE D3; SEROTONIN RECEPTOR AGONISTS;

EID: 84906936535     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-014-3505-6     Document Type: Article

References (96)

1. Albert PR, Le François B (2010) Modifying 5-HT1A receptor gene expression as a new target for antidepressant therapy. Front Neurosci 4:35
2. Alex KD, Pehek EA (2007) Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission. Pharmacol Ther 113:296-320 (Pubitemid 46149046)
3. Alkhatib AH, Dvorkin-Gheva A, Szechtman H (2013) Quinpirole and 8-OH-DPAT induce compulsive checking behavior in male rats by acting on different functional parts of an OCD neurocircuit. Behav Pharmacol 24:65-73
4. Amato D, Stasi MA, Borsini F, Nencini P (2008) Haloperidol both prevents and reverses quinpirole-induced nonregulatory water intake, a putative animal model of psychogenic polydipsia. Psychopharmacol (Berl) 200:157-165
5. Andersen SL, Greene-Colozzi EA, Sonntag KC (2010) A novel, multiple symptom model of obsessive-compulsive-like behaviors in animals. Biol Psychiatry 68:741-747
6. Aouizerate B, Guehl D, Cuny E, Rougier A, Bioulac B, Tignol J, Burbaud P (2004) Pathophysiology of obsessive-compulsive disorder: a necessary link between phenomenology, neuropsychology, imagery and physiology. Prog Neurobiol 72:195-221 (Pubitemid 38591296)
7. Aouizerate B, Guehl D, Cuny E, Rougier A, Burbaud P, Tignol J, Bioulac B (2005)Updated overview of the putative role of the serotoninergic system in obsessive-compulsive disorder. Neuropsychiatr Dis Treat 1:231-43
8. Barnes NM, Sharp T (1999) A review of central 5-HT receptors and their function. Neuropharmacology 38:1083-152 (Pubitemid 29292403)
9. Barr LC, Goodman WK, Price LH (1993) The serotonin hypothesis of obsessive compulsive disorder. Int Clin Psychopharmacol 8(Suppl 2):79-82 (Pubitemid 24063811)
10. Baxter LR Jr (1992) Neuroimaging studies of obsessive compulsive disorder. Psychiatr Clin North Am 15:871-884
11. Ben Pazi A, Szechtman H, Eilam D (2001) The morphogenesis of motor rituals in rats treated chronically with the dopamine agonist quinpirole. Behav Neurosci 115:1301-1317 (Pubitemid 33139137)
12. Bloch MH, Landeros-Weisenberger A, Kelmendi B, Coric V, Bracken MB, Leckman JF (2006) A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Mol Psychiatry 11:622-632 (Pubitemid 43989810)
13. Bos M, Jenck F, Martin JR, Moreau JL, Sleight AJ, Wichmann J, Widmer U (1997) Novel agonists of 5HT2C receptors. Synthesis and biological evaluation of substituted 2-(indol-1-yl)-1-methylethylamines and 2-(indeno[1,2-b]pyrrol-1-yl) -1-methylethylamines. Improved therapeutics for obsessive compulsive disorder. J Med Chem 40:2762-2769 (Pubitemid 27366457)
14. Boulougouris V, Glennon JC, Robbins TW (2008) Dissociable effects of selective 5-HT2A and 5-HT2C receptor antagonists on serial spatial reversal learning in rats. Neuropsychopharmacology 33:2007-2019 (Pubitemid 351832598)
15. Broocks A, Pigott TA, Hill JL, Stephanie C, Grady TA, L'Heureux F, Murphy DL (1998) Acute intravenous administration of ondansetron and m-CPP, alone and in combination, in patients with obsessive-compulsive disorder (OCD): behavioral and biological results. Psychiatry Res 79:11-20 (Pubitemid 28318238)
16. Campbell KM, de Lecea L, Severynse DM, Caron MG, McGrath MJ, Sparber SB, Sun LY, Burton FH (1999) OCD-Like behaviors caused by a neuropotentiating transgene targeted to cortical and limbic D1+ neurons. J Neurosci 19:5044-5053 (Pubitemid 29270139)
17. Carlezon WA Jr, Nestler EJ (2002) Elevated levels of GluR1 in the midbrain: a trigger for sensitization to drugs of abuse? Trends Neurosci 25:610-615
18. Carpenter TL, Pazdernik TL, Levant B (2003) Differences in quinpirole-induced local cerebral glucose utilization between naive and sensitized rats. Brain Res 964:295-301 (Pubitemid 36165154)
19. Charney DS, Goodman WK, Price LH, Woods SW, Rasmussen SA, Heninger GR (1988) Serotonin function in obsessive-compulsive disorder. A comparison of the effects of tryptophan and m-chlorophenylpiperazine in patients and healthy subjects. Arch Gen Psychiatry 45:177-85 (Pubitemid 18052850)
20. Culver KE, Szechtman H, Levant B (2008) Altered dopamine D2-like receptor binding in rats with behavioral sensitization to quinpirole: effects of pre-treatment with Ro 41-1049. Eur J Pharmacol 592:67-72
21. de Leeuw AS, Westenberg HG (2008) Hypersensitivity of 5-HT2 receptors in OCD patients. An increased prolactin response after a challenge with meta-chlorophenylpiperazine and pre-treatment with ritanserin and placebo. J Psychiatr Res 42:894-901
22. Denys D (2006) Pharmacotherapy of obsessive-compulsive disorder and obsessive-compulsive spectrum disorders. Psychiatr Clin North Am 29:553-584
23. Dougherty DD, Rauch SL, Jenike MA (2004) Pharmacotherapy for obsessive-compulsive disorder. J Clin Psychol 60:1195-202 (Pubitemid 39392091)
24. Drai D, Golani I (2001) SEE: a tool for the visualization and analysis of rodent exploratory behavior. Neurosci Biobehav Rev 25:409-426 (Pubitemid 32879298)
25. Drai D, Benjamini Y, Golani I (2000) Statistical discrimination of natural modes of motion in rat exploratory behavior. J Neurosci Methods 96:119-131 (Pubitemid 30138057)
26. Dvorkin A, Perreault ML, Szechtman H (2006) Development and temporal organization of compulsive checking induced by repeated injections of the dopamine agonist quinpirole in an animal model of obsessive-compulsive disorder. Behav Brain Res 169:303-311
27. Dvorkin A, Silva C, McMurran T, Bisnaire L, Foster J, Szechtman H (2010) Features of compulsive checking behavior mediated by nucleus accumbens and orbital frontal cortex. Eur J Neurosci 32:1552-1563
28. Eilam D, Golani I (1989) Home base behavior of rats (Rattus norvegicus) exploring a novel environment. Behav Brain Res 34:199-211 (Pubitemid 19214768)
29. Eilam D, Szechtman H (2005) Psychostimulant-induced behavior as an animal model of obsessive-compulsive disorder: an ethological approach to the form of compulsive rituals. CNS Spectr 10:191-202 (Pubitemid 40489289)
30. Einat H, Szechtman H (1995) Perseveration without hyperlocomotion in a spontaneous alternation task in rats sensitized to the dopamine agonist quinpirole. Physiol Behav 57:55-9
31. Fineberg NA, Gale TM, Sivakumaran T (2006) A review of antipsychotics in the treatment of obsessive compulsive disorder. J Psychopharmacol 20:97-103
32. Fink KB, Göthert M (2007) 5-HT receptor regulation of neurotransmitter release. Pharmacol Rev 59:360-417
33. Flaisher-Grinberg S, Klavir O, Joel D (2008) The role of 5-HT2A and 5-HT2C receptors in the signal attenuation rat model of obsessivecompulsive disorder. Int J Neuropsychopharmacol 11:811-25
34. Gatch MB (2003) Discriminative st imulus effects of m- chlorophenylpiperazine as a model of the role of serotonin receptors in anxiety. Life Sci 73:1347-1367
35. Golani I, Benjamini Y, Eilam D (1993) Stopping behavior: constraints on exploration in rats (Rattus norvegicus). Behav Brain Res 53:21-33 (Pubitemid 23074027)
36. Goodman WK, McDougle CJ, Price LH, Riddle MA, Pauls DL, Leckman JF (1990) Beyond the serotonin hypothesis: a role for dopamine in some forms of obsessive compulsive disorder? J Clin Psychiatry 51(Suppl):36-43, discussion 55-58
37. Goodman WK, McDougle CJ, Price LH, Barr LC, Hills OF, Caplik JF, Charney DS, Heninger GR (1995) m-Chlorophenylpiperazine in patients with obsessive-compulsive disorder: Absence of symptom exacerbation. Biol Psychiatry 38:138-149
38. Graybiel AM, Rauch SL (2000) Toward a neurobiology of obsessive-compulsive disorder. Neuron 28:343-347
39. Greene-Schloesser DM, Van der Zee EA, Sheppard DK, Castillo MR, Gregg KA, Burrow T, Foltz H, Slater M, Bult-Ito A (2011) Predictive validity of a non-induced mouse model of compulsive-like behavior. Behav Brain Res 221:55-62
40. Gross-Isseroff R, Cohen R, Sasson Y, Voet H, Zohar J (2004) Serotonergic dissection of obsessive compulsive symptoms: a challenge study with m-chlorophenylpiperazine and sumatriptan. Neuropsychobiology 50:200-5 (Pubitemid 39279410)
41. Hayes DJ, Greenshaw AJ (2011) 5-HT receptors and reward-related behaviour: a review. Neurosci Biobehav Rev 35:1419-1449
42. Hen I, Sakov A, Kafkafi N, Golani I, Benjamini Y (2004) The dynamics of spatial behavior: how can robust smoothing techniques help? J Neurosci Methods 133:161-172 (Pubitemid 38147768)
43. Hikosaka O, Nakamura K, Sakai K, Nakahara H (2002) Central mechanisms of motor skill learning. Curr Opin Neurobiol 12:217-222 (Pubitemid 34518343)
44. Hinds AL, Woody EZ, Van Ameringen M, Schmidt LA, Szechtman H (2012) When too much is not enough: obsessive-compulsive disorder as a pathology of stopping, rather than starting. PLoS ONE 7:e30586
45. Ho Pian KL, Westenberg HG, den Boer JA, de Bruin WI, van Rijk PP (1998) Effects of meta-chlorophenylpiperazine on cerebral blood flow in obsessive-compulsive disorder and controls. Biol Psychiatry 44:367-70 (Pubitemid 28432649)
46. Hoffman KL, Rueda Morales RI (2012) D1 and D2 dopamine receptor antagonists decrease behavioral bout duration, without altering the bout's repeated behavioral components, in a naturalistic model of repetitive and compulsive behavior. Behav Brain Res 230:1-10
47. Hollander E, DeCaria C, Gully R, Nitescu A, Suckow RF, Gorman JM, Klein DF, Liebowitz MR (1991) Effects of chronic fluoxetine treatment on behavioral and neuroendocrine responses to metachlorophenylpiperazine in obsessive-compulsive disorder. Psychiatry Res 36:1-17
48. Huey ED, Zahn R, Krueger F, Moll J, Kapogiannis D, Wassermann EM, Grafman J (2008) A psychological and neuroanatomical model of obsessive-compulsive disorder. J Neuropsychiatry Clin Neurosci 20:390-408
49. Insel TR (1992) Neurobiology of obsessive compulsive disorder: a review. Int Clin Psychopharmacol 7(Suppl 1):31-33, 31-33
50. Insel TR, Mueller EA, Alterman I, Linnoila M, Murphy DL (1985) Obsessive-compulsive disorder and serotonin: is there a connection? Biol Psychiatry 20:1174-1188 (Pubitemid 16053592)
51. Jimenez-Gomez C, Osentoski A, Woods JH (2011) Pharmacological evaluation of the adequacy of marble burying as an animal model of compulsion and/or anxiety. Behav Pharmacol 22:711-713
52. Joel D (2006) The signal attenuation rat model of obsessive-compulsive disorder: a review. Psychopharmacol (Berl) 186:487-503
53. Joel D, Avisar A, Doljansky J (2001) Enhancement of excessive lever-pressing after post-training signal attenuation in rats by repeated administration of the D1 antagonist SCH 23390 or the D2 agonist quinpirole, but not the D1 agonist SKF 38393 or the D2 antagonist haloperidol. Behav Neurosci 115:1291-1300 (Pubitemid 33139136)
54. Khanna S, John JP, Lakshmi Reddy P (2001) Neuroendocrine and behavioral responses to mCPP in obsessive-compulsive disorder. Psychoneuroendocrinology 26:209-223
55. Kontis D, Tsaltas E, Boulougouris V, Papakosta VM, Kalogerakou S, Papadopoulos S, Papadimitriou G (2008) 5-HT2A and 5-HT2C receptor involvement in the acute effects of mCPP and fluoxetine on persistence behaviour. Int J Neuropsychopharmacol 11:282-282
56. Korff S, Stein DJ, Harvey BH (2008) Stereotypic behaviour in the deer mouse: pharmacological validation and relevance for obsessive compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry 32:348-355 (Pubitemid 351178945)
57. Kurylo DD (2004) Effects of quinpirole on operant conditioning: perseveration of behavioral components. Behav Brain Res 155:117-124
58. Martin JR, Bos M, Jenck F, Moreau J, Mutel V, Sleight AJ, Wichmann J, Andrews JS, Berendsen HH, Broekkamp CL, Ruigt GS, Kohler C, Delft AM (1998) 5-HT2C receptor agonists: pharmacological characteristics and therapeutic potential. J Pharmacol Exp Ther 286:913-924 (Pubitemid 29003485)
59. Modell JG, Mountz JM, Curtis GC, Greden JF (1989) Neurophysiologic dysfunction in basal ganglia/limbic striatal and thalamocortical circuits as a pathogenetic mechanism of obsessive-compulsive disorder. J Neuropsychiatry Clin Neurosci 1:27-36 (Pubitemid 19247050)
60. Murphy DL, Zohar J, Benkelfat C, Pato MT, Pigott TA, Insel TR (1989) Obsessive-compulsive disorder as a 5-HT subsystem-related behavioural disorder. Br J Psychiatry Suppl 15-24
61. Noldus LP, Spink AJ, Tegelenbosch RA (2001) EthoVision: a versatile video tracking system for automation of behavioral experiments. Behav Res Methods Instrum Comput 33:398-414 (Pubitemid 33594754)
62. Papakosta VM, Kalogerakou S, Kontis D, Anyfandi E, Theochari E, Boulougouris V, Papadopoulos S, Panagis G, Tsaltas E (2013) 5-HT2C receptor involvement in the control of persistence in the reinforced spatial alternation animal model of obsessivecompulsive disorder. Behav Brain Res 243:176-83
63. Perreault ML, Graham D, Bisnaire L, Simms J, Hayton S, Szechtman H (2005) Kappa-opioid agonist U69593 potentiates locomotor sensitization to the D2/D3 agonist quinpirole: pre- and postsynaptic mechanisms. Neuropsychopharmacology 31:1967-1981
64. Perreault ML, Seeman P, Szechtman H (2007) Kappa-opioid receptor stimulation quickens pathogenesis of compulsive checking in the quinpirole Sensitization model of obsessive-compulsive disorder (OCD). Behav Neurosci 121:976-991 (Pubitemid 350051300)
65. Pigott TA, Hill JL, Grady TA, L'Heureux F, Bernstein S, Rubenstein CS, Murphy DL (1993) A comparison of the behavioral effects of oral versus intravenous mCPP administration in OCD patients and the effect of metergoline prior to i.v. mCPP. Biol Psychiatry 33:3-14 (Pubitemid 23042675)
66. Pitman RK (1989) Animal models of compulsive behavior. Biol Psychiatry 26:189-198
67. Rajkumar R, Pandey DK, Mahesh R, Radha R (2009) 1-(m-Chlorophenyl) piperazine induces depressogenic-like behaviour in rodents by stimulating the neuronal 5-HT2A receptors: proposal of a modified rodent antidepressant assay. Eur J Pharmacol 608:32-41
68. Richards TL, Pazdernik TL, Levant B (2005) Altered quinpirole-induced local cerebral glucose utilization in anterior cortical regions in rats after sensitization to quinpirole. Brain Res 1042:53-61
69. Saxena S, Bota RG, Brody AL (2001) Brain-behavior relationships in obsessive-compulsive disorder. Semin Clin Neuropsychiatry 6:82-101
70. Schepisi C, De Carolis L, Nencini P (2013) Effects of the 5HT2C antagonist SB242084 on the pramipexole-induced potentiation of water contrafreeloading, a putative animal model of compulsive behavior. Psychopharmacol (Berl) 227:55-66
71. Schilman EA, Klavir O, Winter C, Sohr R, Joel D (2010) The role of the striatum in compulsive behavior in intact and orbitofrontal-cortex-lesioned rats: possible involvement of the serotonergic system. Neuropsychopharmacology 35:1026-1039
72. Seeman P, Schwarz J, Chen JF, Szechtman H, Perreault M, McKnight GS, Roder JC, Quirion R, Boksa P, Srivastava LK, Yanai K, Weinshenker D, Sumiyoshi T (2006) Psychosis pathways converge via D2high dopamine receptors. Synapse 60:319-46 (Pubitemid 44134353)
73. Sesia T, Bizup B, Grace AA (2013) Evaluation of animal models of obsessive-compulsive disorder: correlation with phasic dopamine neuron activity. International Journal of Neuropsychopharmacology: 1-13
74. Shanahan NA, Velez LP, Masten VL, Dulawa SC (2011) Essential role for orbitofrontal serotonin 1B receptors in obsessive-compulsive disorder-like behavior and serotonin reuptake inhibitor response in mice. Biol Psychiatry 70:1039-48
75. Spink AJ, Tegelenbosch RA, Buma MO, Noldus LP (2001) The EthoVision video tracking system - a tool for behavioral phenotyping of transgenic mice. Physiol Behav 73:731-744 (Pubitemid 32885562)
76. Stein DJ (2002) Obsessive-compulsive disorder. Lancet 360:397-405
77. Sullivan RM, Talangbayan H, Einat H, Szechtman H (1998) Effects of quinpirole on central dopamine systems in sensitized and non-sensitized rats. Neuroscience 83:781-9 (Pubitemid 28068898)
78. Szechtman H, Eilam D (2005) Psychiatric models. In:Whishaw IQ, Kolb B (eds) The behavior of the laboratory rat: a handbook with tests. Oxford University Press, New York, pp 462-474
79. Szechtman H, Woody E (2004) Obsessive-compulsive disorder as a disturbance of security motivation. Psychol Rev 111:111-127 (Pubitemid 38157078)
80. Szechtman H, Dai H, Mustafa S, Einat H, Sullivan RM (1994a) Effects of dose and interdose interval on locomotor sensitization to the dopamine agonist quinpirole. Pharmacol Biochem Behav 48:921-928 (Pubitemid 24259822)
81. Szechtman H, Talangbayan H, Canaran G, Dai H, Eilam D (1994b) Dynamics of behavioral sensitization induced by the dopamine agonist quinpirole and a proposed central energy control mechanism [published erratum appears in Psychopharmacology (Berl) 1994Sep;116(1):124]. Psychopharmacol (Berl) 115:95-104
82. Szechtman H, Sulis W, Eilam D (1998) Quinpirole induces compulsive checking behavior in rats: a potential animal model of obsessive-compulsive disorder (OCD). Behav Neurosci 112:1475-1485
83. Szechtman H, Shivji S, Woody EZ (2013) Pathophysiology of obsessive-compulsive disorder: insights from normal function and neurotoxic effects of drugs, infection and brain injury. In: Kostrzewa RM (ed) Handbook of neurotoxicity. Springer London, Limited
84. Szumlinski KK, Allan M, Talangbayan H, Tracey A, Szechtman H (1997) Locomotor sensitization to quinpirole: environment-modulated increase in efficacy and context-dependent increase in potency. Psychopharmacoly (Berl) 134:193-200 (Pubitemid 27522576)
85. Tolkamp BJ, Kyriazakis I (1999) To split behaviour into bouts, log-transform the intervals. Anim Behav 57:807-817 (Pubitemid 29186605)
86. Tolkamp BJ, Allcroft DJ, Austin EJ, Nielsen BL, Kyriazakis I (1998) Satiety splits feeding behaviour into bouts. J Theor Biol 194:235-250 (Pubitemid 28472909)
87. Tucci MC, Dvorkin-Gheva A, Graham D, Amodeo S, Cheon P, Kirk A, Peel J, Taji L, Szechtman H (2013) Effects of the serotonergic agonist mCPP on male rats in the quinpirole sensitization model of obsessive-compulsive disorder (OCD). Psychopharmacol (Berl) 227:277-285
88. Vermeire S, Audenaert K, De Meester R, Vandermeulen E, Waelbers T, De Spiegeleer B, Eersels J, Dobbeleir A, Peremans K (2012) Serotonin 2A receptor, serotonin transporter and dopamine transporter alterations in dogs with compulsive behaviour as a promising model for human obsessive-compulsive disorder. Psychiatry Res Neuroimaging 201:78-87
89. Vezina P, Stewart J (1990) Amphetamine administered to the ventral tegmental area but not to the nucleus accumbens sensitizes rats to systemic morphine: lack of conditioned effects. Brain Res 516:99-106 (Pubitemid 20189205)
90. Westenberg HG, Fineberg NA, Denys D (2007) Neurobiology of obsessive-compulsive disorder: serotonin and beyond. CNS Spectr 12:14-27
91. Wise S, Rapoport JL (1989) Obsessive compulsive disorder - is it a basal ganglia dysfunction? In: Rapoport J (ed) Obsessive compulsive disorder in children and adolescence. American Psychiatric Press, Washington, DC, pp 327-344
92. Woody EZ, Szechtman H (2005) Motivation, time course, and heterogeneity in obsessive-compulsive disorder: response to Taylor, McKay, and Abramowitz (2005). Psychol Rev 112:658-661 (Pubitemid 41151869)
93. Woody EZ, Szechtman H (2011) Adaptation to potential threat: the evolution, neurobiology, and psychopathology of the security motivation system. Neurosci Biobehav Rev 35:1019-1033
94. Yadin E, Friedman E, Bridger WH (1991) Spontaneous alternation behavior: an animal model for obsessive-compulsive disorder? Pharmacol Biochem Behav 40:311-315
95. Zohar J, Mueller EA, Insel TR, Zohar-Kadouch RC, Murphy DL (1987) Serotonergic responsivity in obsessive-compulsive disorder. Comparison of patients and healthy controls. Arch Gen Psychiatry 44:946-51 (Pubitemid 18009649)
96. Zohar J, Chopra M, Sasson Y, Amiaz R, Amital D (2000) Obsessive compulsive disorder: serotonin and beyond. World J Biol Psychiatry 1:92-100